TY  - JOUR
AU  - Thierauf, Julia
AU  - Veit, Johannes A
AU  - Hess, Jochen
AU  - Treiber, Nicolai
AU  - Lisson, Catharina
AU  - Weissinger, Stephanie E
AU  - Bommer, Martin
AU  - Hoffmann, Thomas K
TI  - Checkpoint inhibition for advanced mucosal melanoma.
JO  - European journal of dermatology
VL  - 27
IS  - 2
SN  - 1167-1122
CY  - Montrouge
PB  - Libbey Eurotext
M1  - DKFZ-2017-01086
SP  - 160-165
PY  - 2017
AB  - Whereas anti-PD-1 therapy has demonstrated a significant and durable response against advanced cutaneous melanoma, conventional chemotherapies have shown only minor benefit against advanced mucosal melanoma.To investigate the efficacy of anti-PD-1 therapy in a small cohort of patients with mucosal melanoma of the head and neck.We analysed five patients with mucosal melanoma of the head and neck who received nivolumab or pembrolizumab, at an advanced stage. Expression of PD-L1 and PD-1 in all tumour samples was evaluated immunohistochemically.All patients received at least two cycles of nivolumab or pembrolizumab. The most severe adverse events were categorised as CTCAE (common terminology criteria for adverse events) Grade 2. All patients showed progressive disease after restaging at three and six months, and no partial or complete response was observed. Immunohistochemical staining demonstrated PD-L1 expression in less than 5
LB  - PUB:(DE-HGF)16
C6  - pmid:28174141
UR  - https://inrepo02.dkfz.de/record/120659
ER  -